培美曲塞一线治疗晚期肺腺癌的疗效分析

Efficacy of pemetrexed as first-line treatment for advanced lung adenocarcinoma

目的观察培美曲塞治疗晚期肺腺癌的疗效与安全性。方法分析我院病理确诊为腺癌的晚期肺癌患者70例,随机按1∶1分为培美曲塞组(PC组)和吉西他滨组(GC组),分别接受培美曲塞或吉西他滨联合顺铂治疗,3周为一个周期。主要研究终点:无进展生存期,次要研究终点:客观缓解率、疾病控制率。结果 PC组比较GC组客观缓解率(ORR):42.9%vs 25.7%,疾病控制率:85.7%vs 68.6%,中位无进展生存期:6个月vs.5个月;两组间差异均无统计学意义(P>0.05)。PC组不良反应发生率较GC组明显降低(P<0.05),两组患者治疗后生活质量评分比较均有所提高(P>0.05)。结论培美曲塞和吉西他滨对晚期肺腺癌的疗效相近,但培美曲塞更安全,耐受性更好。

Objective To observe the clinical efficacy and safety of pemetrexed as first-line treatment for ad-vanced lung adenocarcinoma .Methods This study enrolled 70 patients with chemotherapy-naive advanced lung ade-nocarcinoma , and they were randomly divided into the PC group （ cisplatin plus pemetrexed chemotherapy ） and the GC group （gemcitabine plus cisplatin）.One treatment course included 3 weeks.The primary end point was progres-sion free survival and the secondary end points included objective response rate （ ORR ） and disease control rate （ DCR） .Results ORR was 42.9%and 25.7%, and DCR was 85.7% and 68.6% respectively in the PC group and the GC group （P〉0.05）.The median progression-free survival time of the PC and GC groups was 6 months vs. 5 months （P〉0.05）.The incidence of toxicities in the GC group was significantly higher than that in the PC group （P〈0.05）.The quality of life improved in the two groups , but there was no significant difference between the two groups （P〉0.05）.Conclusion Pemetrexed and gemcitabine have similar curative effect for advanced lung adeno-carcinoma , but pemetrexed has better safety and tolerance .